SAH and investigated their associations with the 3-month functional outcome in patients with Fisher Grade III aneurysmal SAH.
Methods

Patients
This study was approved by the National Taiwan University Hospital Committee of Human Research and conducted in accordance with human ethics regulations. The study recruited 18-to 80-year-old patients with Fisher Grade III aneurysmal SAH (the appearance of SAH on CT with hemorrhage of more than 1 mm thickness). Patients were excluded if they had obstructive hydrocephalus caused by intraventricular hemorrhage (IVH) in the third or fourth ventricle, arterial dissection, infectious aneurysm, massive intracerebral hemorrhage (defined as a hematoma volume > 30 ml), uncal brain herniation, meningitis, brain tumor, end-stage renal disease, or spinal cord tumor. Written informed consent was obtained from the patient or from the next of kin of patients with decreased consciousness.
Study Design
The patients recruited in this study received standard treatment, which was provided by an integrated team including neurosurgeons, neurointensivists, and interventional neuroradiologists. The management protocol consisted of resuscitation, early surgical or endovascular obliteration of the aneurysm, standard management of intracranial pressure and neurointensive care, and aggressive medical or endovascular therapy for vasospasm if present. In some cases of acute hydrocephalus with impaired consciousness, an external ventricular drain was inserted before angiography.
After surgery, patients were monitored in the neurointensive care unit. Head CT angiography or conventional angiography was performed when vasospasm was suspected 4, 13 or if neurological deterioration was noted. Chronic hydrocephalus requiring ventriculoperitoneal CSF shunting was defined as a clinical deterioration with no detectable cause other than hydrocephalus occurring after day 14 posthemorrhage, with progressive ventricular size increase and Evans index greater than 0.30. 27 Delayed ischemic neurological deficit (DIND) was defined as clinical deterioration (i.e., a new focal deficit, decrease in the level of consciousness, or both) and/or a new infarct on a CT scan that was not visible on the admission or immediate postoperative scans. 27 Other potential causes of clinical deterioration or hypodensity on CT, such as rebleeding, cerebral edema, retraction injury, ventriculitis, metabolic derangements, and seizures, were rigorously excluded. The functional outcome was evaluated using the Glasgow Outcome Scale (GOS) at 3 months after onset. 5, 10 A GOS score ≤ 3 was defined as an unfavorable functional outcome.
CSF Sample Collection, Preparation, and Analysis
Intrathecal CSF was obtained via lumbar puncture or lumbar drain on the 7th day after SAH. In our treatment protocol, lumbar puncture or lumbar drainage insertion was usually performed at Day 7 because we have found that most events of DIND occur at around 1 week after onset of SAH.
The CSF samples were immediately centrifuged at 900g and 4°C for 20 minutes before being divided into suitable aliquots and snap-frozen at -80°C within 30 minutes. The concentrations of proteins, glucose, and lactate in the CSF samples were determined using an automatic chemistry analyzer. The levels of iron and ferritin were determined using quickauto-neo-Fe (K) (Toshiba-2000FR), and total bilirubin was determined on a Hitachi 7070 chemistry analyzer (also known as a Hitachi 911). The CSF HO-1 concentration rather than activity was determined using a Human HO-1 ELISA Kit (EKS-800, Stressgen/Assay Designs). The concentration of oxyhemoglobin was determined by means of spectrophotometry. In brief, the CSF samples were measured 3 times at each wavelength (A577 and A630), and the mean values of the measurements were used for calculation of the oxyhemoglobin concentrations
Statistics
Statistical analysis was performed using R 2.14.1 software (R Foundation for Statistical Computing). In the statistical testing, a 1-sided p value ≤ 0.05 was considered statistically significant. The distributional properties of continuous variables were expressed as the mean ± SD, median, and interquartile range (IQR), whereas categorical variables were represented as frequency and percentage. In univariate analysis, the differences in the clinical and CSF biochemical parameters between good and poor outcomes were examined using the chi-square test, Fisher exact test, 2-sample t-test, 1-way analysis of variance (ANOVA), Wilcoxon rank-sum test, KruskalWallis test, or log-rank test as appropriate. Next, multivariate analysis was conducted via logistic regression with significant variables from the aforementioned urivariate analysis. The results were used to adjust the clinical significance (adjusted odds ratio) of CSF biomarkers in association with outcome. Finally, generalized additive models (GAMs) were applied to detect the cutoff value of continuous covariates.
Results
During the period between January 2009 and June 2010, a total of 81 patients with aneurysmal SAH were admitted to our hospital. After exclusion of patients who did not met the inclusion/exclusion criteria (n = 26) or who did not consent to participation (n = 14), 41 patients were included in the study. Their mean age was 59 ± 14 years, and 39.0% were male (16 male, 25 female). Of these 41 patients, 20 (48.8%) had acute hydrocephalus, 21 (51.2%) had IVH, and 11 (26.9%) had DIND. In 12 cases (29.3%), the patients underwent transarterial embolization of their aneurysms; the other 29 patients underwent surgical clipping. External ventricular drainage was used in 23 cases (56.9%). By the end of the 3-month follow-up period, 17 patients (41.5%) were identified as having an unfavorable outcome.
In terms of the clinical data, univariate analysis showed that the patients with an unfavorable outcome were older and, as a group, had a higher percentage of admission World Federation of Neurosurgical Societies (WFNS) grades ≥ 3, IVH, and acute hydrocephalus than the patients with a favorable outcome (Table 1) . Multivariate analysis further revealed that age > 60 years (p = 0.029), WFNS ≥ 3 (p = 0.038), and the presence of acute hydrocephalus (p = 0.021) were independent factors associated with an unfavorable outcome. Regarding the CSF data, univariate analysis showed that the patients with an unfavorable outcome had significantly higher levels of HO-1, oxyhemoglobin, bilirubin, ferritin, and lactic acid, a higher WBC count, and a lower percentage of lymphocytes than those with a favorable outcome. After adjusting for the clinical parameters of age, WFNS (≥ or < 3), and the presence of acute hydrocephalus and IVH, a higher level of HO-1 appeared to be the only independent CSF variable associated with an unfavorable outcome (OR 0.920, 95% CI 0.850-0.995, p = 0.038) ( Table 2 ). There was no significant difference in HO-1 levels for SAH patients with or without DIND (71.1 ± 74.7 vs 99.2 ± 102.8 μM, p = 0.34). Figure 1 demonstrates the association of the levels of oxyhemoglobin, ferritin, and bilirubin with individual GOS scores. Among the 4 CSF parameters, HO-1 had the best fit with GOS grade, because HO-1 decreased gradually as the GOS score increased. Furthermore, a GAM plot identified a clinically useful HO-1 cutoff value of 81.2 μM in identifying patients with an unfavorable outcome (64.7% sensitivity, 100% specificity, 100% positive predictive value, 80.0% negative predictive value, and 82.4% accuracy for HO-1 > 81.2 μM as a predictor of unfavorable outcome) (Fig. 2) .
Discussion
Several clinical studies have shown that older patient age, poor neurological grade on admission, greater SAH on CT, and the existence of IVH or the occurrence of vasospasm or DIND are commonly associated with a poor outcome. 2, 3, 20, 21 However, using clinical scales such as the Fisher grade for the amount of blood on head CT, initial Glasgow Coma Scale score, or WFNS grade at admission often provides a crude estimation of the outcome. It is also difficult to precisely measure the amount of blood in the subarachnoid space based on routine imaging programs. In addition, the occurrence of vasospasm may be difficult to detect if not associated with obvious neurological deterioration. Therefore, it would be valuable to identify an appropriate biochemical marker to assist in predicting outcome in the early stages of SAH.
Recently, experimental studies have suggested that posthemorrhagic erythrocyte catabolism is crucially involved in the pathophysiological mechanisms of both early brain injury and delayed vasospasm after SAH. 6, 11, 12, 16 Therefore, the activation of heme metabolism may theoretically reflect the degree of neurological damage and correlate with outcome after SAH. Review of the previous literature shows that ferritin and bilirubin are the 2 most commonly investigated targets among the molecules involved in the heme metabolic pathway in clinical studies. One study showed that the CSF ferritin level peaked between Day 7 and Day 11 after SAH and was significantly correlated with Fisher CT score. 17 Another study reported that level of CSF bilirubin was detectable in the 1st week but then became undetectable in the 2nd week. 18 In contrast, the CSF ferritin level rose gradually and reached a peak between 1 and 2 weeks after SAH.
Regarding the association between the heme metabolic pathway and SAH-mediated neurological complications, one study in which CSF samples were collected from 70 SAH patients showed that patients with shunt-dependent hydrocephalus (SDHC) had significantly higher levels of CSF ferritin than those without SDHC in acute SAH. 26 Another study included 39 patients with Fisher Grade III aneurysmal SAH, 20 of whom developed asymptomatic or symptomatic vasospasm. 25 That study showed that the levels of ferritin and bilirubin were significantly higher in patients with no vasospasm than in patients with vasospasm on Day 5 to Day 7, and thus it was concluded that induction of HO-1 may be responsive for an intrinsic mechanism against vasospasm after the occurrence of SAH. In contrast, a study that included 12 SAH patients and focused on a similar topic showed that patients with vasospasm had higher CSF concentrations of HO-1 than patients without vasospasm. 19 Moreover, most of the aforementioned studies evaluated only 1 or 2 parameters or recruited a relatively small sample size.
In our study, the clinical data showed that older age and the occurrence of acute hydrocephalus were 2 inde- pendent factors related to an unfavorable outcome, which was consistent with several previous studies. In terms of the CSF study, there was a significant difference between the 2 outcome groups (favorable and unfavorable) with respect to most parameters measured. However, a higher level of HO-1 appeared to be the only parameter that remained significantly associated with an unfavorable outcome after adjustment of clinical factors. In addition, an -1, (B) oxyhemoglobin, (C) bilirubin, and (D) ferritin at different GOS scores. The HO-1 levels of patients with GOS scores of 1 and 2 were significantly higher levels than those of patients with higher GOS scores, and the oxyhemoglobin levels of patients with GOS scores of 1 were significantly higher levels than those with the other GOS scores. Importantly, among the 4 parameters, HO-1 showed the best fit with GOS score, as HO-1 decreased gradually as the GOS score increased. **p < 0.01.
81.2-mM cutoff value of effectively predicts an unfavorable outcome. To the best of our knowledge, the clinical significance of the CSF HO-1 concentration as an outcome predictor in SAH patients has not been mentioned before. One recent study also showed that the concentration of HO-1 in CSF obtained from infants and children after severe traumatic brain injury was correlated with injury severity and outcome. 7 Most importantly, our results support the existence of an overall detrimental rather than protective effect of the activation of heme metabolism in the pathogenesis of SAH.
Because heme oxygenase is an enzyme that catalyzes the degradation of heme, it is possible that more bleeding may indicate higher levels of heme oxygenease. 10 However, so far there is no ideal way to precisely quantify the amount of blood in the subarachnoid space. Furthermore, we have examined a series of CSF biomarkers linking to heme metabolism, and only HO-1 had an independent correlation with outcome after adjustment for clinical parameters. Therefore, our data not only support the clinical usefulness of CSF HO-1 levels as an outcome indicator, but also point out a possible independent role of HO-1 in pathogenesis of SAH.
Importantly, although our results showed that HO-1 concentration was positively correlated with poor outcome, the study design (cross-sectional association) does not allow identification of any cause-and-effect relationships for HO-1 in the pathophysiological mechanism of SAH. In fact, several factors that are increased after a stroke are involved in adaptive responses that protect the brain from vascular injury. Examples include neurotrophic factors such as FGF2 9 and the soluble form of receptor for advanced glycation endproducts (investigated in our latest study 28 ), which increase in response to acute brain injury and can reduce brain damage and improve functional outcome in animal stroke models.
There are several possible limitations of our study. First, we measured CSF biochemical markers at only a single time point (7 days after SAH), and thus our data cannot demonstrate the interval changes of those parameters after SAH. However, as we mentioned earlier, several studies have shown an interval change of CSF ferritin and bilirubin after the onset of SAH, and all studies showed that the time to reach peak levels of both parameters was around 1 week. Second, although our data demonstrated an association between high levels of HO-1 and an unfavorable outcome, the causal relationship of the individual molecule involved in heme metabolism and outcome cannot be established based on our cross-sectional study design. Third, it was the occurrence of DIND, rather than the events of vasospasm per se, that was collected in our study database. Therefore, whether there is an association between vasospasm and levels of HO-1 is unknown. Nevertheless, our results did encourage further studies, especially with a basic research animal model, to investigate the possible pathophysiological role of HO-1 in SAH. Fourth, around half of our patients were treated with EVD. Our study did not collect intrathecal CSF before and after EVD, and thus whether this procedure would substantially affect the component of measured protein is uncertain. Finally, ours was a single-hospital study, and thus patient selection bias might be possible. Further study with larger sample sizes and a multicenter study design is necessary to strengthen our findings.
Conclusions
Our study not only supported the importance of HO-1 in the pathogenesis of acute SAH, but also proposed a clinically useful cutoff value of CSF HO-1 as a poor outcome indicator among patients with Fisher Grade III aneurysmal SAH. 
